Skip to main content

Table 2 Incidence rates and adjusted hazard ratios for cancer development

From: The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study

 

Before-matching cohort

Matched cohort

TNF inhibitor cohort (12,491.9 PY)

nbDMARD cohort (117,735.9 PY)

TNF inhibitor cohort (8884.8 PY)

nbDMARD cohort (8422.2 PY)

Event number

81

1769

58

131

IR (1000 person-years)

6.5

15.0

6.5

15.6

aHR (95% CI)

0.492 (0.351, 0.688)

0.379 (0.255, 0.563)

  1. TNF tumor necrosis factor, nbDMARD non-biologic disease-modifying anti-rheumatic drug, PY person-years, IR incidence rate, aHR adjusted hazard ratio, CI confidence interval
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us